secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001193125-26-061412
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa enters $50M ATM equity offering with Rodman & Renshaw; terminates Jefferies facility
--------------------------------------------------------------------------------

- ATM agreement allows up to $50M in common stock sales; company pays 3% commission to sales agent.
- Proceeds intended for clinical development, working capital, and general corporate purposes.
- Prior Jefferies ATM agreement terminated with no sales made; no termination penalties incurred.
- Company not obligated to sell any shares; may suspend or terminate the arrangement at any time.
- Offering registered under effective S-3 shelf (filed May 2024); prospectus supplement filed Feb 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/0001193125-26-061412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/d100198d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-061412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer